Nearly 1 in 10 teens globally have used risky weight loss products, study finds

Experts say the use of such products at a young age can pose both immediate and longer-term health risks.

January 10, 2024 Check out STAT+

Sponsored By

Drew Angerer/Getty Images Advocates expect Supreme Court Idaho abortion decision to fuel efforts to further restrict access Supreme Court case on Idaho abortion access highlights confusion over what constitutes a medical emergency in states with restrictive laws. By Olivia Goldhill and Annalisa Merelli Nearly 1 in 10 teens globally have used 'budget Ozempic' laxatives and other risky weight loss products, per study Nearly1 in 10 adolescents around the globe have used non-prescription weight loss products. Experts warn these products pose health risks. By Theresa Gaffney After grilling Fauci on Covid origins, House Republicans want to consider new rules for foreign research Republicans want to explore tighter inspection and safety requirements for infectious disease work done in foreign labs. By Sarah Owermohle Adobe Opinion: Preventing health care violence in the ER requires moving from safety to security Health care workers like me face violence on a daily basis. We need more than just safety — we need security. By Jay Baruch STAT+ | Bayer's promising menopause drug trial results highlight growing interest in long-neglected condition Veozah, a non-hormonal hot flash treatment by Astellas, may soon face competition as Bayer reports encouraging clinical trial results for elinzanetant. By Annalisa Merelli STAT+ | Heated lawsuit between AdventHealth, MultiPlan attracts hospital lobbyists AdventHealth called MultiPlan an "economic parasite" in a new legal filing. The American Hospital Association also is getting involved. By Bob Herman Verve STAT+ | At JPM, Verve details plot to take genome editing mainstream Verve Therapeutics' CEO says the company wants to edit out heart attacks for the millions at risk of severe cardiovascular disease. By Damian Garde

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser